stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) Return on assets
CRISPR Therapeutics AG's return on assets over the twelve months to 30 September 2026 was −19.0%, up 6.8 percentage points from fiscal 2025 (−25.8%). Over the past ten years it has ranged from −43.4% (fiscal 2018) to 16.5% (fiscal 2021); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of −46.1% and above the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −25.8% | (9.43) |
| FY2024 | −16.4% | (9.51) |
| FY2023 | −6.87% | 19.16 |
| FY2022 | −26.0% | (42.52) |
| FY2021 | 16.5% | 40.59 |
| FY2020 | −24.1% | (32.69) |
| FY2019 | 8.59% | 51.99 |
| FY2018 | −43.4% | (21.22) |
| FY2017 | −22.2% | (12.99) |
| FY2016 | −9.19% | 22.50 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | 85.4% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −5.32% |
| TVTX Travere Therapeutics, Inc. compare | −17.5% |
| CRSP CRISPR Therapeutics AG | −19.0% |
| MANE Veradermics Incorporated compare | −20.9% |
| DNTH Dianthus Therapeutics, Inc. compare | −21.8% |
| DFTX Definium Therapeutics, Inc. compare | −51.4% |
| ERAS Erasca, Inc. compare | −65.3% |
| COGT Cogent Biosciences, Inc. compare | −68.0% |
| Biotechnology industry median | −46.1% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on CRSP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement